Page last updated: 2024-10-15

sparstolonin b

Description

sparstolonin B: selectively blocks TLR2- and TLR4-mediated inflammatory signaling; isolated from a Chinese herb, Spaganium stoloniferum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135659042
SCHEMBL ID16158994
MeSH IDM0561363

Synonyms (9)

Synonym
sparstolonin b
SCHEMBL16158994
sparstolonin b, >=98% (hplc)
4,14-dihydroxy-8,15-dioxatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9(17),10,13-heptaen-12-one
1259330-61-4
HY-116213
CS-0064377
MS-23784
4,10-dihydroxy-3h-pyrano[3,4,5-kl]xanthen-3-one

Research Excerpts

Overview

Sparstolonin B (SsnB) is a TLR antagonist which attenuates cytokine production and improves outcomes in sepsis. It is a novel bioactive compound isolated from Sparganium stoloniferum, an herb historically used in Traditional Chinese Medicine as an anti-tumor agent.

ExcerptReference
"Sparstolonin B is an isocoumarin whose anticancer activity has recently received increasing attention."( Sparstolonin B inhibits pancreatic adenocarcinoma through the NF-κB signaling pathway.
Chen, C; Duan, B; Jiang, X; Liu, X; Liu, Z; Lyu, Y; Yang, F, 2022
)
"Sparstolonin B (SsnB) is a TLR antagonist which attenuates cytokine production and improves outcomes in sepsis."( Altered Toll-Like Receptor Signalling in Children with Down Syndrome.
Balfe, J; Doherty, DG; Franklin, O; Huggard, D; Kelly, L; Koay, WJ; Lagan, N; Leahy, TR; McGrane, F; Melo, AM; Molloy, EJ; Moreno-Oliveira, A; Roche, E; Ryan, E, 2019
)
"Sparstolonin B (SsnB) is an isocoumarin compound isolated from the tubers of both Sparganium stoloniferum and Scirpus yagara. "( Sparstolonin B suppresses lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells.
Cui, X; Duan, J; Fan, D; Liang, Q; Nagarkatti, P; Wu, Q; Yu, F, 2013
)
"Sparstolonin B (SsnB) is a novel bioactive compound isolated from Sparganium stoloniferum, an herb historically used in Traditional Chinese Medicine as an anti-tumor agent. "( Sparstolonin B inhibits pro-angiogenic functions and blocks cell cycle progression in endothelial cells.
Bateman, HR; Fan, D; Lessner, SM; Liang, Q; Rodriguez, V, 2013
)
"Sparstolonin B (SsnB) is a TLR2/TLR4 antagonist that inhibits inflammatory responses in multiple cell types."( Sparstolonin B suppresses rat vascular smooth muscle cell proliferation, migration, inflammatory response and lipid accumulation.
Fan, D; Janicki, JS; Li, J; Liang, Q; Liu, Q; Luo, Y; Wang, D; Yu, F,
)

Treatment

ExcerptReference
"Treatment with Sparstolonin B significantly suppressed toll‑like receptor 4 (TLR4), myeloid differentiation primary response protein 88 (MyD88) and nuclear factor (NF)‑κB protein expression, inhibited NAPDH oxidase 2 protein expression and induced phosphoinositide 3‑kinase and phosphorylated protein kinase B protein expression in the IVDD rat model."( Sparstolonin B prevents lumbar intervertebral disc degeneration through toll like receptor 4, NADPH oxidase activation and the protein kinase B signaling pathway.
Chen, L; Ge, J; Lu, X; Xiang, Z; Yang, Y, 2018
)

Pharmacokinetics

ExcerptReference
" The pharmacokinetic parameters were calculated using Win Nonlin53 software."( Determination of sparstolonin B by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry: application to pharmacokinetic study of sparstolonin B in rat plasma.
Deng, HS; Kang, A; Li, P; Liang, QL; Liu, J; Liu, X; Zou, NS, 2015
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's20 (80.00)24.3611
2020's5 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]